Baidu
map

Stroke:除了降低卒中复发,双抗还能减轻残疾

2020-05-11 杨中华 脑血管病及重症文献导读

TIA 和小卒中早期使用阿司匹林能够降低卒中复发的风险和卒中复发的严重程度。

TIA 和小卒中早期使用阿司匹林能够降低卒中复发的风险和卒中复发的严重程度。对于这类患者,阿司匹林联合氯吡格雷双抗治疗(DAPT)比单独使用阿司匹林进一步降低了卒中复发的风险。不过,人们很少关注这种治疗对功能残疾和卒中严重程度的影响。复发性卒中是TIA和小卒中后残疾的主要原因,因此降低这种风险的治疗方法预计也会降低残疾风险。然而,许多其他因素也会导致TIA和小卒中后的残疾,如出血事件、内科并发症,以及一些小卒中发病时存在神经功能缺损。

2020年3月来自美国的 Brett Cucchiara 等在 Stroke 上公布了他们的研究结果,他们利用 POINT 试验的数据,分析了 DAPT 对残疾的影响。

POINT 试验把发病12h 内的 TIA 或小卒中(NIHSS<=3)的患者随机给予阿司匹林+氯吡格雷的 DAPT 或单独阿司匹林。主要复合终点为卒中、心梗或血管性死亡。本次作者进行了一次探索性事后分析,验讫治疗措施对90天残疾(定义为 mRS >1)的作用。

在90天时,TIA 的患者中9.6%存在残疾,小卒中的患者中18.2%存在残疾。DAPT 组和单独阿司匹林组的总残疾率相似(14.7% vs 14.3%;OR,0.97 95% CI 0.82 - 1.14,P = 0.69)。然而,在发生了主要终点事件的患者中, DAPT 组残疾的比例低于单独阿司匹林组(3% vs 4%;OR,0.73 [95% CI,0.53 - 1.01];P = 0.06);在残疾归因于 Index 事件或复发性卒中的患者中,DAPT 组残疾的比例低于单独阿司匹林组(5.9% vs 7.4%; OR, 0.78 [95% CI, 0.62 – 0.99]; P=0.04)。值得注意的是,归因于 Index 事件的残疾占了这一差异的大部分(4.5% vs 6.0%; OR, 0.74 [95% CI, 0.57–0.96]; P=0.02)。在多因素分析中,年龄、随后的缺血性卒中、女性、高血压和大出血明显与 TIA 后残疾有关;对于卒中患者,女性、高血压、糖尿病、NIHSS、复发性缺血性卒中、随后的心肌梗塞以及严重不良事件与残疾有关。

最终作者认为除了减少急性小卒中和TIA患者的复发性卒中外,DAPT还可能减少卒中相关的残疾。

原始出处:Brett Cucchiara , Jordan Elm, J. Donald Easton, et al. Disability After Minor Stroke and Transient Ischemic Attack in the POINT Trial. Stroke. 2020 Mar;

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=891905, encodeId=bb10891905c1, content=拓宽知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d65c2218916, createdName=120f372am88暂无昵称, createdTime=Tue Oct 13 23:08:57 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391629, encodeId=d3ea13916294a, content=<a href='/topic/show?id=f8ab3603664' target=_blank style='color:#2F92EE;'>#卒中复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36036, encryptionId=f8ab3603664, topicName=卒中复发)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QTZ947pojXuchvvmkkJN0wyBBbA3LVX2WDkgiaJ7cswu9yvA4CB0NicjcrCfBY1zRPkA/132, createdBy=b3812500089, createdName=ms6897892027066920, createdTime=Tue May 12 17:40:01 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487254, encodeId=76de148e254c6, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37461, encryptionId=334b3e46139, topicName=双抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbaa8296156, createdName=yeye5224615, createdTime=Tue May 12 17:40:01 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382709, encodeId=0fe4382e0918, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Mon May 11 08:30:33 CST 2020, time=2020-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026639, encodeId=0c47102663947, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Mon May 11 05:40:01 CST 2020, time=2020-05-11, status=1, ipAttribution=)]
    2020-10-13 120f372am88暂无昵称

    拓宽知识

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=891905, encodeId=bb10891905c1, content=拓宽知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d65c2218916, createdName=120f372am88暂无昵称, createdTime=Tue Oct 13 23:08:57 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391629, encodeId=d3ea13916294a, content=<a href='/topic/show?id=f8ab3603664' target=_blank style='color:#2F92EE;'>#卒中复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36036, encryptionId=f8ab3603664, topicName=卒中复发)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QTZ947pojXuchvvmkkJN0wyBBbA3LVX2WDkgiaJ7cswu9yvA4CB0NicjcrCfBY1zRPkA/132, createdBy=b3812500089, createdName=ms6897892027066920, createdTime=Tue May 12 17:40:01 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487254, encodeId=76de148e254c6, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37461, encryptionId=334b3e46139, topicName=双抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbaa8296156, createdName=yeye5224615, createdTime=Tue May 12 17:40:01 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382709, encodeId=0fe4382e0918, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Mon May 11 08:30:33 CST 2020, time=2020-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026639, encodeId=0c47102663947, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Mon May 11 05:40:01 CST 2020, time=2020-05-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=891905, encodeId=bb10891905c1, content=拓宽知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d65c2218916, createdName=120f372am88暂无昵称, createdTime=Tue Oct 13 23:08:57 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391629, encodeId=d3ea13916294a, content=<a href='/topic/show?id=f8ab3603664' target=_blank style='color:#2F92EE;'>#卒中复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36036, encryptionId=f8ab3603664, topicName=卒中复发)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QTZ947pojXuchvvmkkJN0wyBBbA3LVX2WDkgiaJ7cswu9yvA4CB0NicjcrCfBY1zRPkA/132, createdBy=b3812500089, createdName=ms6897892027066920, createdTime=Tue May 12 17:40:01 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487254, encodeId=76de148e254c6, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37461, encryptionId=334b3e46139, topicName=双抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbaa8296156, createdName=yeye5224615, createdTime=Tue May 12 17:40:01 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382709, encodeId=0fe4382e0918, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Mon May 11 08:30:33 CST 2020, time=2020-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026639, encodeId=0c47102663947, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Mon May 11 05:40:01 CST 2020, time=2020-05-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=891905, encodeId=bb10891905c1, content=拓宽知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d65c2218916, createdName=120f372am88暂无昵称, createdTime=Tue Oct 13 23:08:57 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391629, encodeId=d3ea13916294a, content=<a href='/topic/show?id=f8ab3603664' target=_blank style='color:#2F92EE;'>#卒中复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36036, encryptionId=f8ab3603664, topicName=卒中复发)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QTZ947pojXuchvvmkkJN0wyBBbA3LVX2WDkgiaJ7cswu9yvA4CB0NicjcrCfBY1zRPkA/132, createdBy=b3812500089, createdName=ms6897892027066920, createdTime=Tue May 12 17:40:01 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487254, encodeId=76de148e254c6, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37461, encryptionId=334b3e46139, topicName=双抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbaa8296156, createdName=yeye5224615, createdTime=Tue May 12 17:40:01 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382709, encodeId=0fe4382e0918, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Mon May 11 08:30:33 CST 2020, time=2020-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026639, encodeId=0c47102663947, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Mon May 11 05:40:01 CST 2020, time=2020-05-11, status=1, ipAttribution=)]
    2020-05-11 一天没事干

    很好的学习机会

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=891905, encodeId=bb10891905c1, content=拓宽知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d65c2218916, createdName=120f372am88暂无昵称, createdTime=Tue Oct 13 23:08:57 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391629, encodeId=d3ea13916294a, content=<a href='/topic/show?id=f8ab3603664' target=_blank style='color:#2F92EE;'>#卒中复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36036, encryptionId=f8ab3603664, topicName=卒中复发)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QTZ947pojXuchvvmkkJN0wyBBbA3LVX2WDkgiaJ7cswu9yvA4CB0NicjcrCfBY1zRPkA/132, createdBy=b3812500089, createdName=ms6897892027066920, createdTime=Tue May 12 17:40:01 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487254, encodeId=76de148e254c6, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37461, encryptionId=334b3e46139, topicName=双抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbaa8296156, createdName=yeye5224615, createdTime=Tue May 12 17:40:01 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382709, encodeId=0fe4382e0918, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Mon May 11 08:30:33 CST 2020, time=2020-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026639, encodeId=0c47102663947, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Mon May 11 05:40:01 CST 2020, time=2020-05-11, status=1, ipAttribution=)]
    2020-05-11 健健

    卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!

    0

相关资讯

Stroke:房颤与脑卒中患者认知功能障碍的关系

在未经调整和调整后的分析中,既往卒中患者AF与CI或痴呆之间的相关性可能是持续存在的正相关性。异质性水平限制了这些结果的确定性。

JACC:经导管主动脉瓣置换术后的晚期脑血管事件

中位随访2年后,5.1%的TAVR受者出现LCVEs。大多数情况下LCVEs是缺血性的。

Stroke:血栓的渗透性有利于卒中的病因学诊断

2020年3月来自德国的 Maria 后似乎取决于患者的发病机制.

Heart:经导管二尖瓣介入治疗后的脑血管事件

经导管二尖瓣介入治疗与脑血管事件的发生率较低相关。

Scand J Trauma Resusc Emerg Med:院前卒中护理是否与社会经济地位同有关?

最近的研究显示,卒中结局间存在社会经济差异。在这里,我们调查了院前卒中护理是否与社会经济地位(SES)不同。

Eur Stroke J:抗血栓治疗对卒中或一过性缺血发作和非瓣膜心房颤动患者卒中和其他血栓栓栓塞事件的二级预防的抗栓治疗

缺血性脑卒中或短暂性缺血性发作和非瓣膜心房颤动的患者,其反复发生脑卒中和其他血管事件的风险较高。本指南旨在为这些患者提供抗血栓药物治疗对脑卒中及其他血管结局的二级预防提供建议。

Baidu
map
Baidu
map
Baidu
map